The US Food and Drug Administration (FDA) has approved sodium zirconium cyclosilicate (Lokelma), a highly-selective, oral potassium-removing agent for adults with hyperkalemia. The drug has been shown to reduce potassium levels in patients with chronic kidney disease, heart failure, diabetes and those taking renin-angiotensin-aldosterone system (RAAS) inhibitors.